Botfet / Company detail

RAPP

rejected

Rapport Therapeutics, Inc. Common Stock

biotech

Moat scoreNot available: not scored quality failout of 100
Rejectionquality_fail

The numbers

Financial metrics

Quality gate and thesis context
Roic-25.2%
Gross Margin0.0%
Revenue Cagr0.0%
Fcf Conversion79.0%
Fcf Yield-7.0%
Interest Coverage0.0x
Market Cap B$1.3B
PeNot available: not applicable loss making
Quality PassFail
Founder LedNo
Thesis AlignedYes
Moat QuantNot available: not scored quality fail

Why it may endure

Moat breakdown

Quant: Not available: not scored quality fail · Curator: Not available: not scored quality fail
Market Share StabilityNot available: not scored quality fail
Network EffectsNot available: not scored quality fail
Pricing PowerNot available: not scored quality fail
Regulatory MoatNot available: not scored quality fail
Switching CostsNot available: not scored quality fail
ConvictionNot available: not scored quality fail
LeadershipNot available: not scored quality fail
VisionNot available: not scored quality fail
← Back to the full screener